



Welcome to the  
Imricor Annual Meeting

Wednesday, 4 May 2022 (AEST)  
Tuesday, 3 May 2022 (CDT)



# Please submit questions at any time throughout the meeting

To ask a question select the 'Q&A' icon



Q & A

Select the topic your question relates to.

Type your question into the chat box at the bottom of the screen and press 'Send'

Your question will be sent immediately for review

Broadcast Vote **Q & A** Documents

Your questions(s)

You may enter a question using the field below.

3 Adoption of Remuneration Report ▼

Enter your question here

24 character(s)

Send



# Voting online at the virtual meeting

When the Chair declares the poll open, select the 'Vote' icon and the voting options will appear on your screen



Vote



To vote, select your voting direction. A tick will appear to confirm receipt of your vote

To change your vote, select 'Click here to change your vote' and press a different option to override.

Broadcast	<b>Vote</b>	Q & A	Documents

---

**Items of Business**

**2A Re-elect Mr John Brown as a Director**

FOR	AGAINST	ABSTAIN
-----	---------	---------

---

**2B Re-elect Mr Peter Nolan as a Director**

FOR	AGAINST	ABSTAIN
-----	---------	---------



# Imricor's Board of Directors



Steve Wedan  
President and CEO,  
and Chair



Mark Tibbles  
Deputy Chair and Lead  
Independent Director



Anita Messal  
Non-executive Director



Peter McGregor  
Non-executive Director

# Chair's Address





# Delivering on our Strategic Plan

1

More **sites**  
to do procedures



Grow Installed Base

2

More **procedures**  
per site



Expand indications

3

Higher **ASP** and  
margin improvement



Expand geographies



New product development



## FY21 Highlights

- Contracted five new sites across Europe, bringing the total number of sites to fourteen
- Performed procedures as restrictions allowed through COVID waves
- Current contracted site status:

Current Site Status	Number of Sites
<b>Operational</b>	6
<b>Installation complete</b> (preparing to commence or re-commence procedures)	2
<b>Preparing for installation</b> (e.g. ordering equipment, scheduling training, etc.)	7

Two additional sites are under construction, but are not yet under contract with Imricor





## FY21 Highlights continued

- Appointed Regional Health Care Group (RHCG) in Australia to help facilitate TGA and Medsafe approvals
  - Medsafe approval received for all Imricor products in New Zealand
  - Received TGA approval on Imricor's Advantage-MR System, Vision-MR catheter under review
- Entered into an exclusive distribution agreement with RHCG for consumables, and non-exclusive distribution of capital equipment in Australia and New Zealand
- Filed an application for an Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA)
- Successfully raised A\$16.5 million via an oversubscribed institutional placement at \$1.00 per CDI
- Successfully raised A\$1 million in October via an oversubscribed security purchase plan (SPP) offered to eligible CHES Depositary Interest (CDI) holders in Australia and New Zealand
- Entered into two Sales Distribution Agreements with:
  - NordicNeuroLab AS (NordicNeuroLab), a leading maker of MRI compatible in-room monitors
  - MiRTLE Medical, LLC (MiRTLE), maker of an MRI-compatible 12 lead ECG system and
- Completed a strategic investment in MiRTLE





# Site expansion plans underpinned by strong pipeline

Helios Hospital Berlin-Buch,  
Germany



Semmelweis University Heart and  
Vascular Centre, Hungary



German Heart Centre Berlin, Germany



Charité Medical University Virchow-  
Klinikum Campus, Germany



Henry Dunant Hospital Centre, Greece



Policlinico Casilino, Italy  
(new in 2022)



Dresden Heart Centre,  
Germany

Helios Leipzig Heart Centre,  
Germany

Lübeck University Hospital,  
Germany

Rhön Clinic Bad Neustadt Campus,  
Germany

Münster University Hospital,  
Germany

South Paris Cardiovascular Institute,  
France

Maastricht University Medical Centre,  
The Netherlands

Amsterdam University Medical Center,  
The Netherlands

Haga Hospital,  
The Netherlands

The Lausanne University Hospital,  
Switzerland

The Heart and Diabetes Centre NRW,  
Germany



## Partnering to drive growth in clinical sites

Imricor has entered into a number of agreements that promote future iCMR site adoption



NordicNeuroLab





# Developing product lines to support expanded indications & margin improvement

## Steerable Sheath and Transseptal Needle

- Preclinical trials underway
- Undergoing final device testing
- Preparing for approval submission as part of VT trial in 2022
- Preparing for CE mark submission in parallel with VT trial

The steerable sheath and transseptal needle are intended to be used together in procedures where access to the left side of the heart is required and the physician opts to access the left side by crossing the intra-atrial septum



## Diagnostic Catheter

- Utilising advancements from the next generation ablation catheter to create a more consistent product line for physicians and reduce production costs to drive a higher gross margin
- Currently in 3<sup>rd</sup> round of technical documentation review with Notified Body
- CE mark expected in 2022

A diagnostic catheter can sense electrical signals flowing through the heart and provide cardiac stimulation but is not used for ablation. A diagnostic and ablation catheter is required to perform atrial flutter procedures - currently sold by Imricor in a two-catheter set comprising two ablation catheters.





# A strong and growing market in cardiac ablation

A large global addressable market with high growth potential supported by favourable growth drivers

## Drivers of Global Catheter Ablation Market



- Increased incidence of cardiac disease




- Shift towards minimally invasive procedures



- Cost effectiveness of catheter ablation as treatment option

## Breakdown of Ablation Procedures

Ablation Procedure Types EU 2019





# Focus Initiatives for 2022

## Site Growth

- Increased engagement with **Electrophysiologists** to drive demand for iCMR labs
- Increased engagement with **Philips and Siemens** sales forces to help deliver the pipeline of iCMR labs

## Utilisation

- **Initiate procedures** at each contracted site
- **Increase procedure volume** at each contracted site

## Market Expansion

- Progress approval of **VT indications** through preclinical and clinical trials
- Progress **TGA approval** for Imricor's Vision-MR Ablation Catheter in Australia
- Progress Investigational Device Exemption (IDE) from the **FDA** in the US to begin clinical trial

## Products

- Submit second-generation ablation catheter for CE mark approval
- Submit steerable sheath and transseptal needle for CE mark approval
- Receive CE mark approval for diagnostic catheter
- Progress development of MRI compatible biopsy system



# Disclaimer

The material contained in this presentation is intended to be general background information on Imricor Medical Systems Inc (“Imricor”) and its activities.

The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (US GAAP) and are denominated in US dollars.

This presentation may contain statements that constitute “forward-looking statements” within the meaning of Section 21E of the US Securities Exchange Act of 1934. Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding our intent, belief or current expectations with respect to our business and operations, market conditions, results of operations and financial condition.

We use words such as ‘will’, ‘may’, ‘expect’, ‘intend’, ‘seek’, ‘would’, ‘should’, ‘could’, ‘continue’, ‘plan’, ‘estimate’, ‘anticipate’, ‘believe’, ‘probability’, ‘risk’, ‘aim’, or other similar words to identify forward-looking statements. These forward-looking statements reflect our current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond our control, and have been made based upon management’s expectations and beliefs concerning future developments and their potential effect upon us. There can be no assurance that future developments will be in accordance with our expectations or that the effect of future developments on us will be those anticipated. Actual results could differ materially from those which we expect, depending on the outcome of various factors. Factors that may impact on the forward-looking statements made include, but are not limited to, those described in the section titled ‘Risk factors’ in Imricor’s prospectus dated 7 August 2019. When relying on forward-looking statements to make decisions with respect to us, investors and others should carefully consider such factors and other uncertainties and events. We are under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction.